AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04407585 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Covid-19 swab PCR test
Description: Participants satisfying machine learning test criteria will be asked to take a swab test for Covid-19.
Study NCT03717129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genvoya Oral dose
Description: Single Genvoya oral dose directly observed
Study NCT03717129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genvoya Crushed Dose
Description: Single Genvoya crushed tablet in water directly observed
Study NCT01822288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tibolone
Description: Tibolone 2.5 mg once a day for patients with menopausal syndrome (self-paid)
Study NCT01822288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol & medroxyprogesterone acetate
Description: Estradiol \& medroxyprogesterone acetate once a day for patients with menopausal syndromes, for patients without the need for self-paid drug
Study NCT00603720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NAME
Description: nitric oxide synthase inhibitor 4mg/kg infusion over 30-60 minutes prior to PET imaging
Study NCT00603720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-NAME
Description: nitric oxide synthase inhibitor 4mg/kg infusion over 30-60 minutes prior to PET imaging
Study NCT00603720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Arginine
Description: aids in nitric oxide production
Study NCT00603720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: alpha agonist; 10 μg/kg/min infusion during PET study
Study NCT02889003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone + TKI
Study NCT01847053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cinnamon
Description: Intervention will be both ground cinnamon and cinnamon extract.
Study NCT01847053 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oatmeal
Description: Oatmeal control, around 70g; without cinnamon
Study NCT02020382 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: qPCR diagnostic KIT of microRNAS
Description: testing qPCR diagnostic KIT of microRNAS from colonic biopsies
Study NCT03753620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: simultaneous fMRI and EEG + peripheral measures
Description: Hemodynamic activity recorded with fMRI, cerebral electric activity recorded with EEG as well as peripheral physiological parameters will be recorded during music listening.
Study NCT03753620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG and peripheral measures
Description: cerebral electric( with EEG) as well as peripheral physiological parameters will be recorded during music listening.
Study NCT00368160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: eszopiclone 3 mg
Study NCT00368160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT02940821 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrushing
Description: Mechanical plaque removal
Study NCT02940821 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoridated Dentifrice (.15% sodium monofluorophosphate)
Description: Fluoridated dentifrice application
Study NCT02940821 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoridated Dentifrice Whitening System (.454% stannous fluoride with 2% hydrogen peroxide)
Description: Application of Tooth Whitening Agent in Dentifrice
Study NCT02940821 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whitening (4.5% hydrogen peroxide)
Description: Application of Whitening Agent
Study NCT02940821 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Other Fluoridated Dentifrice (.454% stannous fluoride)
Description: Fluoridated dentifrice application
Study NCT01828788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study NCT01828788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00890487 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: hyaluronic acid pill
Description: pill, 220 mg, once a day, three months
Study NCT04543487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Description: Therapeutic touch was applied twice to the women in the intervention group in addition to routine practices. The first application was performed in the active phase of the first stage of labour, and the second was done in the second stage of labour.
Study NCT01724073 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leafy vegetable-fish sauce
Study NCT01724073 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leafy vegetable-fish/liver sauce
Study NCT01724073 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Misola
Study NCT03272126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: vitamin D given as bolus versus daily dosing
Study NCT03272126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical looking as vitamin D
Study NCT02482077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF+RBV
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
Study NCT02482077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF+DCV
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60mg tablet administered once daily.
Study NCT02482077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: Ledipasvir 90 mg /Sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily
Study NCT00777946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren 300 mg
Description: Aliskiren 300 mg tablet taken orally once a day with a glass of water.
Study NCT00777946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/Amlodipine 300/5 mg
Description: Aliskiren/Amlodipine 300/5 mg tablet taken orally once a day with a glass of water.
Study NCT00777946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/Amlodipine 300/10 mg
Description: Aliskiren/Amlodipine 300/10 mg taken orally once a day with a glass of water.
Study NCT00777946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Aliskiren
Description: Placebo to Aliskiren tablet taken orally once a day.
Study NCT00777946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Aliskiren/Amlodipine
Description: Placebo to Aliskiren/Amlodipine taken orally once a day.
Study NCT02684357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
Study NCT02684357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ustekinumab
Description: Ustekinumab pre-filled syringe, administered by subcutaneous (SC) injection
Study NCT02684357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for risankizumab
Description: Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
Study NCT02684357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo for risankizumab
Description: Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
Study NCT02684357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for ustekinumab
Description: Placebo for ustekinumab pre-filled syringe, administered by subcutaneous (SC) injection
Study NCT02684357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for ustekinumab
Description: Placebo for ustekinumab pre-filled syringe, administered by subcutaneous (SC) injection
Study NCT01853982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam
Study NCT01853982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/Tazobactam
Study NCT04558749 — intervention group
Intervention type: OTHER
Intervention: State-trait anxiety inventory scale
Description: This scale is composed of two parts, part one measures anxiety traits and part two measures anxiety state. Each part comprises 20 statements. This scale is a (4) point scale, with a score ranging a minimum of 20 grades to a maximum of 80 grades.
Study NCT04558749 — intervention group
Intervention type: OTHER
Intervention: Edinburgh Postnatal Depression Scale (EDPS)
Description: The EPDS is a self-report measure that focuses on the cognitive symptoms of depression. It excludes somatic items that might generate false positives both during pregnancy and after childbirth.7 The EPDS consists of 10 items, each scored 0-3 points, with a potential scale score of 0-30.
Study NCT01300962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMK120
Description: BKM120 PO 50, 80 or 100mg every day for each day of each 21 day cycle. Number of cycles: until progression of disease; unacceptable toxicity, withdrawal or death.
Study NCT01300962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 875-1250mg/m2 PO BID for two weeks followed by one week rest every three week cycle. Number of cycles: until progression of disease, unacceptable toxicity, withdrawal or death.
Study NCT01300962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: BYL719 200mg PO BID for 21 days (3 weeks) in combination with capecitabine 1000 mg/m2 PO BID for 2 weeks
Study NCT01300962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: trastuzumab infusion on day 1 of each cycle.
Study NCT01300962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: lapatinib daily for 21 days in each cycle.
Study NCT00907790 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care (Control Group)
Study NCT00907790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Self-Management (CSM)
Description: Comprehensive Self-Management includes 8 sessions that cover education, diet, relaxation training, and cognitive behavioral strategies as they related to symptoms of IBS
Study NCT00436033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: milnacipran
Study NCT00436033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01658826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIC316
Description: 100 mg oral administration
Study NCT01658826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AIC316
Description: 100 mg oral administration
Study NCT01658826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: 500 mg oral administration
Study NCT01658826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Description: 500 mg oral administration
Study NCT00475033 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Description: 13-valent pneumococcal conjugate vaccine administered at 2-, 4-, 6-, and 12 months of age.
Study NCT00475033 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine
Description: 7-valent pneumococcal conjugate vaccine administered at 2-, 4-, 6-, and 12 months of age.
Study NCT01315496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunoglobulin G
Description: Immunoglobulin 1.5-2g/Kg/3days
Study NCT01315496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Immunoglobulin G
Description: Immunoglobulin 1.5-2g/Kg/3days
Study NCT04025567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vancomycin
Description: 1,500 mg total daily dose, on days 1-21 of every 28 days cycle.
Study NCT03868488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery tasks
Description: All participants need to finish both visual imagery tasks and auditory imagery tasks. Visual imagery tasks and auditory imagery tasks will be carried out at intervals to avoid the influence of different tasks. The sequence of imagery tasks will be counterbalanced across participants.
Study NCT04790019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low energy availability
Description: Participants will be provided with food to eat every day and will not be permitted to consume any other calorie containing foods or beverages. This amount of energy contained within the food provided will be one third of that contained in the food provided in the control condition (45 kilo-calories per kilogram of fat-free mass per day) and will be standardized between and within participants for carbohydrate, protein and fat composition.
Study NCT04790019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High impact jumping
Description: Participants will perform a brief session of high impact jumping every morning (10 maximum effort vertical counter-movement jumps, and 5 maximum effort lateral drop jumps in each direction) and a similar session of high impact jumping every evening (20 maximum effort vertical counter-movement jumps).
Study NCT03794570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood flow restriction therapy - with Delfi Personalized Tourniquet System
Description: Physical therapy performed with Blood flow restriction therapy tourniquet inflated to 80% limb occlusion pressure
Study NCT03794570 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham blood flow restriction therapy - with Delfi Personalized Tourniquet System
Description: Physical therapy performed with Blood flow restriction therapy tourniquet inflated to only minimal pressure
Study NCT02664727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The effects of acute exercise in heavy drinkers
Description: A group of heavy drinkers and a group of healthy controls (individuals without alcohol use disorders) will cycle on a cycle ergometer for 30 min at 50-60% of HRR. Before and immediately after exercise blood will be drawn and psychological and physiological parameters will be measured.
Study NCT02664727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The effects of acute exercise in alcoholic patients
Description: A group of alcoholic patients (10-14 days after detoxification) and a group of healthy controls (individuals without alcohol use disorders) will cycle on a cycle ergometer for 30 min at 55-60% of HRmax. Before and immediately after exercise blood will be drawn and psychological and physiological parameters will be measured.
Study NCT01783847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (EPO)
Description: 4000 units per vial
Study NCT01783847 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Just observation
Study NCT01783847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methyl prednisolone
Description: 250 mg every 6 hours for 3 days.
Study NCT04633798 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IPL/Lipiflow
Description: To treat patients with MGD using intense pulsed light combined with lipiflow
Study NCT04633798 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IPL/MGX
Description: To treat patients with MGD using intense pulsed light combined with meibomian gland massage
Study NCT03730636 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCT dosage
Description: Measurement of PCT concentration will be performed every two days and the ATB therapy will be stopped when PCT level reaches a value equal or below 0.5ng/mL.
Study NCT00612469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Fluoride
Description: Topical application of 1.23% sodium fluoride to the dentition, every 24 hours, during 6 consecutive days
Study NCT00612469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vancomycin hydrochloride
Description: Topical application of 3% vancomycin hydrochloride to the dentition, every 24 hours, during 6 consecutive days
Study NCT00612469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vancomycin hydrochloride
Description: Topical application of 10% vancomycin hydrochloride to the primary dentition, every 24 hours, during 6 consecutive days
Study NCT00612469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine digluconate
Description: Topical application of 1% chlorhexidine digluconate to the dentition, every 24 hours, during 6 consecutive days
Study NCT03584568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perspective Taking Reappraisal
Description: Interventions involving 1) appreciating relational insights; 2) enhancing self-awareness; 3) empathetic understanding of care-recipient; 4) integrating self-care and caring for others and 5) negotiation.
Study NCT03584568 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Basic Skill Building
Description: These skill-building exercises are commonly used in psycho-education programs for caregivers:monitoring mood and activities, relaxation techniques and scheduling pleasant events, basic communication with the care recipient, communicating the caregivers' own needs with other family member or related persons including helpers and professional staff.
Study NCT03584568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic Skill Building
Description: These skill-building exercises are commonly used in psycho-education programs for caregivers:monitoring mood and activities, relaxation techniques and scheduling pleasant events, basic communication with the care recipient, communicating the caregivers' own needs with other family member or related persons including helpers and professional staff.
Study NCT02049164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR08
Study NCT02049164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03788083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimix
Description: Intratumoral TriMix injection
Study NCT03788083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intratumoral placebo injection
Study NCT03527368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted feeding
Description: Participants consume food earlier in the day
Study NCT03527368 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual feeding pattern
Description: Participants consume food later in the day
Study NCT00676377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine
Description: 2.5 mg of neostigmine intravenously in 250 ml normal saline over a period of thirty minutes ,Half Life 3 Hours
Study NCT00676377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline Placebo
Study NCT04461483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 Tablets
Study NCT04461483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-935 placebo-matching tablets
Study NCT04623970 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Treatment
Description: Comprehensive dental care (restorative treatmen, crowns, pulp therapy, fissure sealant and teeth extraction for pediatric patients under the deep sedation
Study NCT01932567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Study NCT01932567 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical impedance tomography
Study NCT02217332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexpramipexole
Description: Dexpramipexole capsule-shaped film-coated tablets at the dose strength of 150 mg administered orally as 1 tablet twice daily (300 mg/day)
Study NCT02780154 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ (7G8) Challenge
Description: PfSPZ (7G8) is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
Study NCT02780154 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ (NF54) Challenge
Description: PfSPZ (NF54) is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
Study NCT05539274 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: human papilloma virus testing and genotyping in cervical cancer cases
Description: an observational analytical prospective cross-sectional study was managed from July 2019 to July 2022 on 70 cervical cancer patients collected from gyne-oncology unit in Shatby obstetrics and gynecology university hospital of Alexandria medical school after taking a written consent and following approval by Alexandria medical school institutional ethics committee. All patients were subjected to full history taking as age, gravidity, parity, contraceptive history, medical disease, detailed marital history and smoking. Collection of the sample from all cases of the study for human papilloma virus testing and genotyping was done after diagnostic workup and before treatment of the study cases at any time in post-menopausal women and at mid cycles period in premenopausal women by cervical smear using PAP spatula and endocervical brush.